Clinical Trial

Prediction of Effectiveness of rTMS Application in Alzheimer's Patients

Study acronym: PRIM-A

Recruiting

Record status

This record was last updated May 2, 2025 (before its estimated May 15, 2025 completion). Its status may not reflect the trial's current state.

Summary

Since pharmacological methods are insufficient in the treatment processes of Alzheimer's disease, non-pharmacological methods such as Transcranial Magnetic Stimulation (TMS) have started to be tried as a treatment option as in other neurological and psychiatric diseases. Repeated (rTMS) offers a potential treatment pathway for neurological and psychiatric illnesses. rTMS benefit rate may vary depending on many factors such as the region where it is applied, the progression and the disease degree. The possible effects of TMS on Alzheimer's pathophysiology and modification of disease process (neuroprotective, anti-inflammatory and antioxidant) will also be revealed through blood samples taken from patients before and after treatment. These approaches also constitute the original value of our study.

Protocol Amendment History 4 amendments

This ClinicalTrials.gov record has been amended 4 times since 2023-07-27; most recent amendment 2025-04-30.

Trial Details

NCT Number	NCT05977088
Lead Sponsor	Istanbul Medipol University Hospital Collaborators: Bezmialem Vakif University, Saglik Bilimleri Universitesi
Conditions	Alzheimer Disease
Enrollment	40 participants
Start Date	2022-02-16
Primary Completion	2025-05-15 (estimated)
Study Completion	2025-12-30 (estimated)
Updated on ClinicalTrials.gov	2025-05-02